Clinical trial Recruiting at 2 sites Observational Ages 18 and up

Evaluating the Oscar Catheter for Treating Peripheral Arterial Disease

Official title: Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Peripheral Multifunctional Catheter for the Dilatation of Lesions in the Femoral, Popliteal and Infrapopliteal Arteries

Run by Biotronik AG · NCT06758921 · Data updated 2026-11-12

This study is testing a new catheter to see if it can safely help people with blocked arteries in their legs feel better after treatment.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment200 (estimated)
SponsorBiotronik AG
Industry-sponsored
Locations16 sites (Graz and 15 other locations)
StatusRecruiting
StartedDecember 19, 2024
Main results expectedDecember 20, 2025
Study endsJanuary 20, 2026
Registry record updatedJanuary 6, 2025
Trial IDNCT06758921 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older with significant arterial stenosis and specific Rutherford classifications.

Probably not a fit

Patients with less than 70% stenosis or those with certain anatomical restrictions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety and clinical performance of the Oscar Peripheral Multifunctional Catheter in patients with lesions in the femoral, popliteal, and infrapopliteal arteries. It will evaluate standard care practices, procedural outcomes, and in-hospital complications associated with endovascular interventions. The primary endpoint focuses on procedural success, defined by successful lesion crossing and minimal residual stenosis, alongside the absence of complications during the procedure.

Why it matters

Potential benefit: If successful, this study could improve treatment outcomes for patients with Peripheral Arterial Disease by confirming the effectiveness of a new catheter technology.

How similar studies have gone: Previous studies have shown promising results with similar catheter technologies, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Subject ≥18 years old
2. Subject has provided written informed consent
3. Subject has Rutherford classification 2 to 6
4. Reference vessel diameter ≥2 and ≤7 mm
5. Target lesion(s) has stenosis \>70% by visual assessment
6. Multiple consecutive single lesions with a healthy segment(s) of ≤ 3cm in-between will be considered one lesion.

   Above the knee (ATK) group:
7. Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau)
8. At least one below-knee artery patent to the ankle
9. Successful treatment of inflow iliac stenosis to the target lesion. Inflow lesion stenosis can be treated during the same procedure as per local standard of care. The inflow lesion(s) must be treated first, prior to consideration of treatment of the target lesion. Subject can be enrolled if the inflow lesion(s) are treated and result in ≤30% residual stenosis and no evidence of embolization or significant complications.

   Below the knee (BTK) group:
10. Target lesions involve arteries below the tibial plateau
11. Successful treatment of inflow vessel (from ipsilateral iliac to the target lesion) resulting in ≤30% residual stenosis with no evidence of embolization or significant complications

Exclusion Criteria:

1. Subject has a single target lesion that involves both ATK and BTK segments.
2. Subject not suitable for receiving endovascular procedures of lower limb arteries.
3. Prior planned major amputation in the target limb (i.e., above the ankle).
4. Subject with previous bypass surgery of target vessel.
5. History of any open surgical procedure within the past 30 days.
6. Planned vascular surgery procedure within the next 30 days after the ATK and/or BTK procedure on the target limb.

   Note: The inflow vessels can be treated on the day of the procedure.
7. Subject has Oscar IFU listed contraindication (such as uncorrected bleeding disorders, sepsis).
8. Subject under dialysis.
9. Subject currently enrolled in another investigational device, biologic, or drug trial in which the primary endpoint has not yet been reached.
10. Subject lacking capacity to provide informed consent.
11. Subject under judicial protection, tutorship, or curatorship (for France only).

Where it's running

  • LKH Univ. -Klinikum Graz, Ambulanz für Angiologie
    Graz, Austria
    Recruiting
  • AZ Saint Blasius
    Dendermonde, Belgium
    Recruiting
  • Onze Lieve Vrouwziekenhuis
    Aalst, Belgium
    Not yet recruiting
  • ZOL Ziekenhuis Oost Limburg
    Genk, Belgium
    Not yet recruiting
  • University Hospital Ghent
    Ghent, Belgium
    Not yet recruiting
  • vzw AZ Groeninge
    Kortrijk, Belgium
    Not yet recruiting
Show 10 more locations
  • Hopital Saint Joseph
    Paris, France
    Not yet recruiting
  • Karolinen-Hospital Arnsberg
    Arnsberg, Germany
    Not yet recruiting
  • Sankt Gertrauden-Krankenhaus
    Berlin, Germany
    Not yet recruiting
  • Universitätsklinikum Tübingen
    Tübingen, Germany
    Not yet recruiting
  • Semmelweis University
    Budapest, Hungary
    Not yet recruiting
  • Policlinico Abano Terme
    Abano Terme, Italy
    Not yet recruiting
  • Azienda Usl Toscana sud est
    Arezzo, Italy
    Not yet recruiting
  • ospedaliero-universitaria Senese
    Siena, Italy
    Not yet recruiting
  • Hospital Universitario de Guadalajara
    Guadalajara, Spain
    Not yet recruiting
  • Ospedale Regionale civico EOC di Lugano
    Lugano, Switzerland
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.